XSHE
300147
Market cap537mUSD
Oct 09, Last price
5.49CNY
1D
0.55%
1Q
-40.13%
Jan 2017
-56.83%
IPO
-69.36%
Name
Xiangxue Pharmaceutical Co Ltd
Chart & performance
P/E
—
P/S
2.27
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.14%
Rev. gr., 5y
-12.28%
Revenues
1.60b
-14.16%
Net income
-1.39b
L+62.15%
CFO
140m
+668.28%
Dividend
Jun 23, 20200.046 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Xiangxue Pharmaceutical Co., Ltd. is actively involved in the full pharmaceutical lifecycle within China, from scientific research and product development to sourcing, production, and market distribution. The company's product portfolio notably includes its branded Xiangxue antivirotic oral liquids. Beyond these pharmaceutical offerings, it also provides a variety of healthcare supplements and comprehensive wellness solutions, such as specialized food and beverage items. Xiangxue Pharmaceutical has forged a strategic alliance with 111, Inc., with the aim of advancing an "Internet + Medicine" framework tailored for China's traditional Chinese medicine industry. The firm was established in 1997 and its main operations are based in Guangzhou, China.
Key people
Chief Financial Officer · since 2016
Yonghui Wang
Chairman of the Board, General Manager · since 2007
Lun Zeng
Deputy General Manager · since 2013
Bin Huang
Deputy General Manager, Secretary of the Board, Director · since 2013
Shumei Chen
Director · since 2010
Weihua Huang
Director · since 2013
Wenhui Tan
Director · since 2010
Weiyang Zhong
Director · since 2009
Wei Huang
Independent Director · since 2009
Jian Wang
Independent Director · since 2013
Lan Yang
Independent Director · since 2013
Headquarters & legal address
广州市萝岗区广州经济技术开发区科学城金峰园路2号
广州市, GD 100000
CN
广州市, GD 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||